InsiderTrades

Form 4 for KYTX Kyverna Therapeutics, Inc.

Accepted 2024-02-14 00:00:00 ET · period of report 2024-02-12 · accession 0000950170-24-015479 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2024-02-14 2024-02-12 KYTX Vida Ventures GP III, L.L.C. 10% C - Cnv Deriv — +4.52M 4.52M New —
DMI 2024-02-14 2024-02-12 KYTX Vida Ventures GP III, L.L.C. 10% P - Purchase $22.00 +253.1K 583 New +$5.57M
DMI 2024-02-14 2024-02-12 KYTX Vida Ventures GP III, L.L.C. 10% C - Cnv Deriv $0.00 -20.59M 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-12 C A 4,523,924 — 4,523,924 I By Vida Ventures, LLC — — (F1) Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. (F2) The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any.
2 Common Common Stock 2024-02-12 P A 252,553 $22.00 252,553 I By Vida Ventures III, L.P. — — (F3) The shares of the Issuer's Common Stock are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
3 Common Common Stock 2024-02-12 P A 583 $22.00 583 I By Vida Ventures III-A, L.P. — — (F4) The shares of the Issuer's Common Stock are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
4 Derivative Series B Redeemable Convertible Preferred Stock 2024-02-12 C D 7,356,162 $0.00 0 I By Vida Ventures, LLC — · — to — 1,616,348 Common Stock (F2) The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. (F5) The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.
5 Derivative Series A-2 Redeemable Convertible Preferred Stock 2024-02-12 C D 8,830,901 $0.00 0 I By Vida Ventures, LLC — · — to — 1,940,388 Common Stock (F2) The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. (F5) The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.
6 Derivative Series A-1 Redeemable Convertible Preferred Stock 2024-02-12 C D 4,401,771 $0.00 0 I By Vida Ventures, LLC — · — to — 967,188 Common Stock (F2) The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. (F5) The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.